博文
ASCO2024：抗体偶联药物治疗HER2阳性晚期乳腺癌
||
ASCO2024：抗体偶联药物治疗HER2阳性晚期乳腺癌进展
https://blog.sciencenet.cn/blog-280034-1446080.html
上一篇：他汀引起肌肉疼痛
下一篇：反复肺栓塞，患者能否死里逃生？
https://mp.weixin.qq.com/s/0eiyK1bHvGqOMN_blLGZqA
http://www.pubmedplus.cn/P/SearchQuickResult?wd=d40f6ccd-80c1-4c4a-9d62-434396e8a315
| 01. | Humans | 211 篇 | 65.732% |
| 02. | Female | 173 篇 | 53.894% |
| 03. | Breast Neoplasms | 162 篇 | 50.467% |
| 04. | Receptor, ErbB-2 | 149 篇 | 46.417% |
| 05. | Trastuzumab | 103 篇 | 32.087% |
| 06. | Antibodies, Monoclonal, Humanized | 82 篇 | 25.545% |
| 07. | Immunoconjugates | 79 篇 | 24.611% |
| 08. | Ado-Trastuzumab Emtansine | 70 篇 | 21.807% |
| 09. | Antineoplastic Agents | 69 篇 | 21.495% |
| 10. | Maytansine | 55 篇 | 17.134% |
https://blog.sciencenet.cn/blog-280034-1446080.html
上一篇：他汀引起肌肉疼痛
下一篇：反复肺栓塞，患者能否死里逃生？
